Thank you for attending THSNA 2026. The virtual meeting is now closed.
Use this page to browse all contributing authors.
Presentations for Cihan Ay
Mim8 Prophylaxis in Adults and Adolescents with Hemophilia A: 52-Week Efficacy and Safety Outcomes from the Phase 3 FRONTIER2 Study |
From Efficacy to Experience: 52-Week Patient-Reported Outcomes with Mim8 in Adolescents and Adults with Hemophilia A with or without Inhibitors (FRONTIER2) |